<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0034-7523</journal-id>
<journal-title><![CDATA[Revista Cubana de Medicina]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Cuban de Med]]></abbrev-journal-title>
<issn>0034-7523</issn>
<publisher>
<publisher-name><![CDATA[Centro Nacional de Información de Ciencias MédicasEditorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0034-75232024000100007</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[La hiperhomocisteinemia como factor de riesgo en las enfermedades vasculares obstructiva]]></article-title>
<article-title xml:lang="en"><![CDATA[Hyperhomocysteinemia as a Risk Factor in Obstructive Vascular Diseases]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Denis de Armas]]></surname>
<given-names><![CDATA[Reynaldo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Torres Yribar]]></surname>
<given-names><![CDATA[Wilfredo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cepero Llauger]]></surname>
<given-names><![CDATA[Kali]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alonso Rodríguez]]></surname>
<given-names><![CDATA[Celia Ángela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Clínico Quirúrgico Docente Hermanos Ameijeiras  ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<volume>63</volume>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0034-75232024000100007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S0034-75232024000100007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S0034-75232024000100007&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción: La homocisteina es considerada como un factor aterogénico en diversas patologías como las enfermedades cardiovasculares y cerebrovasculares. La hiperhomocisteinemia es una condición de causa variable como factor de riesgo en las enfermedades vasculares obstructivas.  Objetivo: Estudiar el aumento de los niveles de homocisteina en sangre como indicador de riesgo de las enfermedades vasculares obstructivas.  Métodos: Se realizó un estudio prospectivo-analítico de las variaciones de los niveles séricos de hemograma completo en pacientes, con diagnóstico de enfermedades vasculares obstructivas ingresados en el Hospital Hermanos Ameijeiras en el año 2022. La muestra estuvo comprendida por 100 pacientes. La confiabilidad fue un 95 %, el poder estadístico de 80 % y un 25 % de la exposición al factor a evaluar, un odds ratio estimado de 5,00 y una relación de 1:1, (50 casos y 50 controles).  Resultados: En el estudio predominaron los pacientes con más de 50 años, pero no se detectó diferencia significativa con respecto al sexo. La cardiopatía isquémica fue la EVO de mayor incidencia. La hiperhomocisteinemia constituyó un excelente marcador de EVO en los pacientes estudiados a diferencia de los controles.  Conclusiones: En el estudio se demostró una asociación positiva estadísticamente significativa entre la hiperhomocisteinemia y las enfermedades vasculares obstructivas, lo cual confirma el valor de la Hc como predictor de riesgo de esta enfermedad.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction: Homocysteine is considered an atherogenic factor in various diseases such as cardiovascular and cerebrovascular diseases. Hyperhomocysteinemia is a condition of variable cause as a risk factor in obstructive vascular diseases.  Objective: To study the increase in homocysteine levels in the blood as a risk indicator for obstructive vascular diseases.  Methods: A prospective-analytical study was carried out on the variations in serum levels of complete blood count in patients, with a diagnosis of obstructive vascular diseases, who were admitted to Hermanos Ameijeiras Hospital in 2022. The sample consisted of 100 patients. The reliability was 95%, the statistical power was 80% and 25% of the exposure to the factor to be evaluated, an estimated odds ratio of 5.00 and a ratio of 1:1, (50 cases and 50 controls).  Results: Patients over 50 years of age predominated in the study, but no significant difference was detected with respect to sex. Ischemic heart disease was the OVD with the highest incidence. Hyperhomocysteinemia was an excellent marker of VOD in the patients studied, unlike controls.  Conclusions: The study demonstrated a statistically significant positive association between hyperhomocysteinemia and obstructive vascular diseases, confirming the value of Hc as a risk predictor for this disease.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[enfermedad vascular oclusiva]]></kwd>
<kwd lng="es"><![CDATA[cardiopatía isquémica]]></kwd>
<kwd lng="es"><![CDATA[homocisteina]]></kwd>
<kwd lng="es"><![CDATA[hiperhomocisteinemia]]></kwd>
<kwd lng="en"><![CDATA[occlusive vascular disease]]></kwd>
<kwd lng="en"><![CDATA[ischemic heart disease]]></kwd>
<kwd lng="en"><![CDATA[homocysteine]]></kwd>
<kwd lng="en"><![CDATA[hyperhomocysteinemia]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martin]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Fause]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enfermedad Cardiovascular, primera causa de muerte en México y el mundo]]></article-title>
<source><![CDATA[Arch Cardiol Mex]]></source>
<year>2017</year>
<volume>77</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>91-3</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="">
<collab>Organización Mundial de la Salud</collab>
<article-title xml:lang=""><![CDATA[Prevention of Cardiovascular Disease]]></article-title>
<source><![CDATA[Guidelines fo assessment and management of total cardiovascular risk]]></source>
<year>2007</year>
<publisher-loc><![CDATA[Ginebra ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mancia]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[de Backer]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Dominiczak]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fagard]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Germano]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Grassi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Directrices de 2007 para el tratamiento de la hipertensión arterial de la Sociedad Europea de Hipertensión (ESH) y de la Sociedad Europea de Cardiología (ESC)]]></article-title>
<source><![CDATA[J hipertensos]]></source>
<year>2007</year>
<volume>25</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1105-87</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sosa]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dislipidemias]]></article-title>
<source><![CDATA[ACIMED]]></source>
<year>2009</year>
<volume>20</volume>
<numero>6</numero>
<issue>6</issue>
</nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pearson]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Blair]]></surname>
<given-names><![CDATA[SN]]></given-names>
</name>
<name>
<surname><![CDATA[Daniels]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Eckel]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Feria]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Fortmann]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[AHA Guidelines for Primary Prevention for Cardiovascular Disease and Stroke]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2002</year>
<volume>106</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>388-91</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ingelsson]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Schaefer]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Contois]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[McNamara]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Sullivan]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Keyes]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical utility of different lipid measures for prediction of coronary heart disease in men and women]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2007</year>
<volume>298</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>776-84</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="">
<collab>Fundación Española del Corazón (FEC)</collab>
<source><![CDATA[Factores de riesgo cardiovascular]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moat]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[McDowell]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Homocysteine and endothelial function in human studies]]></article-title>
<source><![CDATA[Semin Vasc Med]]></source>
<year>2005</year>
<volume>5</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>172-82</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jin]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Caldwell]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Li-Masters]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Caldwell]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Homocysteine induces endothelial dysfunction via inhibition of arginine transport]]></article-title>
<source><![CDATA[J Physiol Pharmacol]]></source>
<year>2007</year>
<volume>58</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>191-206</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gil Núñez]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Homocisteina: ¿factor de riesgo vascular?]]></article-title>
<source><![CDATA[Neurología]]></source>
<year>2004</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-4</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferket]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
<name>
<surname><![CDATA[Colkesen]]></surname>
<given-names><![CDATA[EB]]></given-names>
</name>
<name>
<surname><![CDATA[Visser]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Sprinkle]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kraaijenhagen]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Steyerbeg]]></surname>
<given-names><![CDATA[EW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systematic review of guidelines on cardiovascular risk assessment: Which recommendations should clinicians follow for a cardiovascular health check?]]></article-title>
<source><![CDATA[Arch Intern Med.]]></source>
<year>2010</year>
<volume>170</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>27-40</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Greenland]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Alpert]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Beller]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Benjamín]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Budoff]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Fayad]]></surname>
<given-names><![CDATA[ZA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2010</year>
<volume>122</volume>
<page-range>2748-64</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nevado Jr]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Imasa]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Homocysteine predicts adverse clinical outcomes in unstable angina and non-ST elevation myocardial infarction: implications from the folate intervention in non-ST elevation myocardial infarction and unstable angina study]]></article-title>
<source><![CDATA[Coron Artery Dis.]]></source>
<year>2008</year>
<volume>19</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>153-61</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vizzardi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Nodari]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fiorina]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Metro]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cas Dei]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Plasma homocysteine levels and late outcome in patients with unstable angina]]></article-title>
<source><![CDATA[Cardiology]]></source>
<year>2017</year>
<volume>107</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>354-9</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meye]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Schumann]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wagner]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gross]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of homocysteine on the levels of caveolin-1 and Enos in caveolae of human coronary artery endothelial cells]]></article-title>
<source><![CDATA[Atherosclerosis]]></source>
<year>2007</year>
<volume>190</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>256-63</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Segovia]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cobos]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Enguix]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluación de un método inmunonefelométrico competitivo para la cuantificación de la homocisteína]]></article-title>
<source><![CDATA[Rev Lab Clín]]></source>
<year>2008</year>
<volume>1</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>13-6</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wald]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Law]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Morris]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis]]></article-title>
<source><![CDATA[BJM]]></source>
<year>2002</year>
<volume>325</volume>
<page-range>1202-6</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18.</label><nlm-citation citation-type="journal">
<collab>World Medical Association Declaration of Helsinki</collab>
<article-title xml:lang=""><![CDATA[Ethical Principles for Medical Research Involving Human Subjects]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2013</year>
<volume>310</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>1-95</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
